Noxxon Pharma (Germany) a clinical-stage biopharmaceutical company focused on the development of aptamers for the treatment of inflammation and hematological indications closed a $2.6M Series D financing, bringing the total round to $42.6M. Participants include NGN Capital, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin, Dow Venture Capital, Fcp Medical BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt and Dieckell Group.